IASLC

CT lung cancer screening substantially reduces lung cancer deaths among asymptomatic patients at high risk for developing lung cancer.

New approaches are needed in the future to further improve outcomes with targeted therapy in NSCLC.

Pathologic analysis of tumor tissue has led to the improved understanding of the molecular drivers of NSCLC.

Interim data from a phase 2 trial suggests that MET inhibitor tepotinib has antitumor activity and a tolerable safety profile in advanced MET exon 14 skipping mutated NSCLC.

An analysis of the phase 3 FLAURA trial demonstrated that osimertinib efficacy was not affected by PD-L1 tumor expression.

A retrospective study suggested that irAEs with second-line nivolumab are associated with PFS and OS in patients with advanced NSCLC.

Despite promising prior data on nintedanib, the addition of the drug to a standard regimen did not improve survival in patients with a specific type of lung cancer.

Outcomes improved in patients across all categories of PD-L1 tumor proportion scores in the pembrolizumab/chemotherapy group.

Adding the checkpoint inhibitor atezolizumab to chemotherapy prolonged overall survival significantly better than chemotherapy alone in patients with ES-SCLC.

When it comes to progression-free survival, patients appeared to fare better with brigatinib than they did with crizotinib, although the phase 3 trial has not yet concluded.